Skip to main content
Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
2.780
-0.150 (-5.12%)
Nov 13, 2026, 4:00 PM EST - Market closed

Company Description

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.

The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen.

The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio, Inc.
Adicet Bio logo
CountryUnited States
Founded1947
IndustryBiotechnology
SectorHealthcare
Employees102
CEOChen Schor

Contact Details

Address:
131 Dartmouth Street, 3rd Floor
Boston, Massachusetts 02116
United States
Phone650 503 9095
Websiteadicetbio.com

Stock Details

Ticker SymbolACET
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001720580
CUSIP Number007002207
ISIN NumberUS0070022076
Employer ID81-3305277
SIC Code2834

Key Executives

NamePosition
Dr. Blake Aftab Ph.D.Senior Vice President and Chief Scientific Officer
Dr. Lloyd Klickstein M.D., Ph.D.Interim Chief Medical Officer and Director
Brian Nicholas Harvey M.B.A.Chief Financial Officer
Dr. Donald Healey Ph.D.Chief Technology Officer
Amy LockeChief Human Resource Officer

Latest SEC Filings

DateTypeTitle
Nov 13, 20268-KCurrent Report
Nov 5, 202610-QQuarterly Report
Nov 5, 20268-KCurrent Report
Oct 28, 2026SCHEDULE 13G/AFiling
Oct 23, 2026SCHEDULE 13GFiling
Sep 28, 20268-KCurrent Report
Sep 8, 20268-KCurrent Report
Sep 1, 20268-KCurrent Report
Aug 14, 2026SCHEDULE 13G/AFiling
Aug 5, 202610-QQuarterly Report
View All SEC Filings